Doctor and patient

Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.

Approach

Benefit

Pursue multiple programmes
  • Increase potential success rate
  • Mitigate development risk
Seek collaboration partners
  • Spread financial cost and risk
  • Introduce specialist research expertise

Develop programmes to pre-clinical/
early clinical development

  • Minimise ongoing development risk
  • Move up value chain
  • Potential for higher deal values
  • @Sareumplc Latest tweet

    Roche's discontinuation of its CHK1 inhibitor, RG7741 (aka Genentech's GDC-0575), means this mechanism is now a two… https://t.co/xq9zzVT44p via @Sareumplc
    View more